(Q33649435)

28 July 2017

1 reference

title

Antiandrogen treatment of polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

28 July 2017

main subject

1 reference

1 reference

Rittmaster RS

1

1 reference

28 July 2017

publication date

1 June 1999

1 reference

Endocrinology and Metabolism Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

28

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

409-421

1 reference

How hairy are hirsute women?

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Cyproterone acetate for severe hirsutism:results of a double-blind dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study**Sponsored by the Canadian Fertility Research Association and funded by a grant-in-aid from Berlen Laboratories Limited, Canada.††T

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Predictors of clinical response in hirsute women treated with spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial**Supported in part by Schering-Plough, Pointe-Claire, Québec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Hormonal effects of flutamide in young women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of the efficacy of spironolactone**Spironolactone (Aldactone; Searle, Chicago, IL). versus flutamide††Flutamide (Eulexin; Schering Plough Laboratories, Heist, Belgium). in the treatment of hirsutism‡‡Presented in part at the 3rd Wo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Clinical assessment of body hair growth in women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Spironolactone therapy during human pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Side-effects of spironolactone therapy in the hirsute woman

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women**Supported in part by National Institutes of Health grant HD-17519-01A1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Adrenal and gonadal androgen secretion in normal females

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Spironolactone and Endocrine Dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Characterization, expression, and immunohistochemical localization of 5 alpha-reductase in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Regulation of androgen receptor and 5 alpha-reductase in the skin of normal and hirsute women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Treatment of hirsutism and acne with cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of Sequential Cyproterone Acetate/Estrogen Versus Spironolactone/Oral Contraceptive in the Treatment of Hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Clinical updates in hair

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Hair regrowth. Therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

CD8+ lymphocytic pneumonitis in a patient receiving cyproterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Finasteride in the treatment of hirsutism: new therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Drug-induced hair loss and hair growth. Incidence, management and avoidance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

Paradoxical effects of the anti-androgen cyproterone acetate on lipid and lipoprotein metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970077-3

7 January 2021

10.1016/S0889-8529(05)70077-3

Identifiers

DOI

1 reference

release_ibsgsg3zgvevdk3z6md7qiitue

28 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ibsgsg3zgvevdk3z6md7qiitue

24 November 2022

mapped directly with Wikidata item

1 reference